✅ Prescription Required
Rx Palladia 10 mg x 30
Palladia® (toceranib phosphate) is a veterinary prescription tyrosine kinase inhibitor (TKI) and the first FDA-approved oral chemotherapy for dogs. It is primarily indicated for the treatment of mast cell tumors (MCTs) in dogs, helping to shrink tumors and slow disease progression. Palladia® may also be prescribed off-label for other types of cancers under veterinary supervision.
Key Details:
-
Strength & Count: 10 mg tablets; 30 ct.
-
Class: Antineoplastic (tyrosine kinase inhibitor).
-
Indication (Dogs): Treatment of cutaneous mast cell tumors with or without regional lymph node involvement.
-
Canine/Feline/Other Species Safety: Approved for dogs only. Not approved for cats, horses, or other animals.
-
Use Only Under Vet Supervision: Federal law restricts this drug to use by or on the order of a licensed veterinarian. Chemotherapy medication—handle with care and avoid direct contact. Not for human use.
-
Contraindications/Cautions: Do not use in breeding, pregnant, or lactating dogs. Use with caution in dogs with gastrointestinal issues, hypertension, or liver/kidney disease. Side effects may include diarrhea, vomiting, loss of appetite, lameness, or weight loss. Regular bloodwork is required during therapy.
-
Storage: Store at 59–86°F (15–30°C). Keep in original container. Protect from moisture and light.
Regulatory: Prescription required; federal law restricts this drug to use by or on the order of a licensed veterinarian.
Keep away from children and other household pets.
This item is not returnable or refundable.
Sold in Qty. of 1 (30 ct.).
| Product type: |
Animal Health & Wellness > Medicine |
| Brand: |
Palladia |
| Size: |
10mg |
| Status: |
Available |
| Animal type: |
Dog |
| Ingredients: |
Toceranib Phosphate. |
| Storage & Disposal: |
Store at controlled room temperature 20° to 25° C (68° to 77° F). |
| Cautions & Warnings: |
PALLADIA may cause vascular dysfunction which can lead to edema and thromboembolism, including pulmonary thromboembolism. Discontinue drug until clinical signs and clinical pathology have normalized. To assure vasculature homeostasis, wait at least 3 days after stopping drug before performing surgery. Do not use in dogs used for breeding, or for pregnant or lactating bitches. Potential Side Effects: Diarrhea, appetite loss, lameness, weight loss, bloody stool Serious and sometimes fatal gastrointestinal complications including gastrointestinal perforation have occurred rarely in dogs treated with PALLADIA (see Adverse Reactions). If gastrointestinal ulceration is suspected, stop drug administration and treat appropriately. Human warnings: NOT FOR USE IN HUMANS. KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN. Children should not come in contact with PALLADIA. Keep children away from feces, urine, or vomit of treated dogs. To avoid exposure to drug, wash hands with soap and water after administering PALLADIA and wear protective gloves to prevent direct contact with feces, urine, vomit, and broken or moistened PALLADIA tablets. Place all waste materials in a plastic bag and seal before general disposal. If eyes are accidentally exposed to the drug, rinse eyes with water immediately. In case of accidental ingestion by a person, seek medical advice immediately, show the package insert or label to the physician. Gastrointestinal discomfort such as vomiting or diarrhea may occur if this drug is accidentally ingested. Pregnant women, women who may become pregnant, or nursing mothers should pay special attention to these handling precautions. (See handling instructions above.) PALLADIA, like other drugs in its class, prevents the formation of new blood vessels in tumors. In a similar manner, PALLADIA may affect blood vessel formation in the developing fetus and may harm an unborn baby (cause birth defects). For pregnant women, accidental ingestion of PALLADIA may have adverse effects on pregnancy. |
| Dosage instructions: |
Administer an initial dosage of 3.25 mg/kg (1.48 mg/lb) body weight, orally every other day (see Table 1). Dose reductions of 0.5 mg/kg (to a minimum dose of 2.2 mg/kg (1.0 mg/lb) every other day) and dose interruptions (cessation of PALLADIA for up to two weeks) may be utilized, if needed, to manage adverse reactions (see Table 2 as well as Warnings and Precautions). Adjust dose based on approximately weekly veterinary assessments for the first 6 weeks and approximately every 6 weeks, thereafter. PALLADIA may be administered with or without food. Do not split tablets. |
| Color: |
Blue |
| Weight: |
1.00 |
| Dimension (L x W x H): |
4 x 4 x 4 |
| Prescription required: |
YES |
| GTIN: |
087219102534 |
